Jenburkt Pharmaceuticals Limited (BOM:524731)

Market Cap	4.86B
Revenue (ttm)	1.49B
Net Income (ttm)	314.06M
Shares Out	4.41M
EPS (ttm)	71.16
PE Ratio	15.47
Forward PE	n/a
Dividend	15.30 (1.41%)
Ex-Dividend Date	Jul 23, 2024

Volume	805
Average Volume	1,096
Open	1,050.00
Previous Close	1,049.80
Day's Range	1,030.05 - 1,097.00
52-Week Range	735.20 - 1,375.00
Beta	0.43
RSI	62.24
Earnings Date	May 26, 2025

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. It offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. The company offers its products under the Allerzine, CartiSafe Forte, Eberjen, EC...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 752
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524731

Financial Performance

In 2023, Jenburkt Pharmaceuticals's revenue was 1.42 billion, an increase of 3.82% compared to the previous year's 1.37 billion. Earnings were 259.77 million, an increase of 5.57%.